middle.news

Immutep Accelerates Global Lung Cancer Trial with 38% Patient Enrolment

8:42am on Tuesday 16th of December, 2025 AEDT Biotechnology
Read Story

Immutep Accelerates Global Lung Cancer Trial with 38% Patient Enrolment

8:42am on Tuesday 16th of December, 2025 AEDT
Key Points
  • 289 patients enrolled globally, 38% of target
  • Over 120 clinical sites activated in 27 countries
  • First US clinical sites approved post-FDA Project Optimus
  • Futility analysis scheduled for Q1 2026
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about IMM
OPEN ARTICLE